VJHemOnc is committed to improving our service to you

iwCLL 2019 | Highlights from iwCLL 2019: MRD and novel therapies

VJHemOnc is committed to improving our service to you

Lydia Scarfò and William Wierda

William Wierda, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, and Lydia Scarfo, MD, from Vita-Salute San Raffaele University, Milan, Italy, discuss the utility of MRD as an intermediate endpoint in chronic lymphocytic leukemia (CLL) treatment. The speakers touch on immuno-chemotherapy and novel therapies introduced at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter